vTv Therapeutics Inc (VTVT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
vTv Therapeutics Inc stock (VTVT) is currently trading at $38.30. vTv Therapeutics Inc PS ratio (Price-to-Sales) is 14852.65. Analyst consensus price target for VTVT is $53.33. WallStSmart rates VTVT as Sell.
- VTVT PE ratio analysis and historical PE chart
- VTVT PS ratio (Price-to-Sales) history and trend
- VTVT intrinsic value — DCF, Graham Number, EPV models
- VTVT stock price prediction 2025 2026 2027 2028 2029 2030
- VTVT fair value vs current price
- VTVT insider transactions and insider buying
- Is VTVT undervalued or overvalued?
- vTv Therapeutics Inc financial analysis — revenue, earnings, cash flow
- VTVT Piotroski F-Score and Altman Z-Score
- VTVT analyst price target and Smart Rating
vTv Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
vTv Therapeutics Inc (VTVT) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
vTv Therapeutics Inc (VTVT) Key Strengths (0)
Supporting Valuation Data
vTv Therapeutics Inc (VTVT) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 14852.6x annual revenue
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Moderate institutional interest at 32.71%
Supporting Valuation Data
vTv Therapeutics Inc (VTVT) Detailed Analysis Report
Overall Assessment
This company scores 17/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 0 register as strengths (avg 0/10) while 5 fall into concern territory (avg 3.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (14852.65), Price/Book (2.23) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -78.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -78.90% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VTVT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VTVT's Price-to-Sales ratio of 14852.65x trades 1256% above its historical average of 1095.73x (98th percentile), historically expensive. The current valuation is 5% below its historical high of 15605.72x set in Mar 2026, and 3622498% above its historical low of 0.41x in Aug 2019. Over the past 12 months, the PS ratio has expanded from ~67.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for vTv Therapeutics Inc (VTVT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
vTv Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Spending 22971% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -9M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact vTv Therapeutics Inc.
Bottom Line
vTv Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About vTv Therapeutics Inc(VTVT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.